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Abstract
Dipeptidyl peptidase IV (DPP-4) enzyme is responsible for the degradation of incretins that
stimulates insulin secretion and hence inhibition of DPP-4 becomes an established
approach for the treatment of type 2 diabetics. We studied the interaction between DPP-4
and its inhibitor drugs (sitagliptin 1, linagliptin 2, alogliptin 3, and teneligliptin 4) quantitatively
by using fragment molecular orbital calculations at the RI-MP2/cc-pVDZ level to analyze the
inhibitory activities of the drugs. Apart from having common interactions with key residues,
inhibitors encompassing the DPP-4 active site extensively interact widely with the hydropho-
bic pocket by their hydrophobic inhibitor moieties. The cumulative hydrophobic interaction
becomes stronger for these inhibitors and hence linagliptin and teneligliptin have larger
interaction energies, and consequently higher inhibitory activities, than their alogliptin and
sitagliptin counterparts. Though effective interaction for both 2 and 3 is at S0
2
subsite, 2 has a
stronger binding to this subsite interacting with Trp629 and Tyr547 than 3 does. The pres-
ence of triazolopiperazine and piperazine moiety in 1 and 4, respectively, provides the inter-
action to the S2 extensive subsite; however, the latter’s superior inhibitory activity is not only
due to a relatively tighter binding to the S2 extensive subsite, but also due to the interactions
to the S1 subsite. The calculated hydrophobic interfragment interaction energies correlate
well with the experimental binding affinities (KD) and inhibitory activities (IC50) of the DPP-4
inhibitors.
Introduction
Dipeptidyl peptidase IV (DPP-4) is the enzyme responsible for the degradation of incretins
such as glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide,
which stimulate insulin secretion from pancreatic beta cells of the islets of Langerhans and
suppress glucagon secretion [1–3]. Since type 2 diabetes is due to insufficient insulin produc-
tion, inhibition of DPP-4, rather than insulin and its secretalogues, now becomes a well-
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tolerated therapeutic route for the treatment of type 2 diabetes because it improves plasma glu-
cose metabolism efficiently and safely without hypoglycemia. Subsequently, a new class of oral
hypoglycemic agents for the treatment of type 2 diabetes were emerged and these are called
DPP-4 inhibitors, which restrain the action of DPP-4 thereby prolonging incretin effect in vivo
[4].
X-Ray crystal structures of DPP-4 complex with several inhibitors (sitagliptin 1 [5], lina-
gliptin 2 [6], alogliptin 3 [7], teneligliptin 4, [8], saxagliptin 5 [9], and vildagliptin 6 [10]) have
been reported in recent years. The schematic structures of all these DPP-4 inhibitors are given
in Fig 1. Nabeno et al. [10] determined the co-crystal structure of vildagliptin 6 with DPP-4 by
Fig 1. Schematic structure of the DPP-4 inhibitors: (a) sitagliptin, (b) linagliptin, (c) alogliptin, (d) teneligliptin, (e) saxagliptin, and (f)
vildagliptin.
doi:10.1371/journal.pone.0166275.g001
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X-ray studies and compared the binding modes of all these six launched inhibitors in DPP-4
[10]. These authors also studied the relationship between binding interactions of these six
inhibitors with DPP-4 and their inhibitory activities based on structural biology. The interac-
tion between DPP-4 and its inhibitors were qualitatively studied also by Scapin and others
[11]. Recently, Schnapp et al. [12] investigated the binding kinetics and thermodynamics of
DPP-4 inhibitors using surface plasmon resonance (SPR) and isothermal titration calorimetry
(ITC). Nevertheless, there is no report detailing the interactions between the DPP-4 and its
inhibitors, especially at molecular level, quantitatively.
The DPP-4 inhibitors bind to the DPP-4-GLP-1 interacting site and hence these inhibitors
may be considered as protein-protein interaction (PPI) inhibitors. It has been reported that
the evolved PPI inhibitors tend to be larger, highly hydrophobic, very rigid, and contain multi-
ple aromatic rings [13]. Understanding the interaction involving such inhibitors therefore
necessitates accurate estimation of hydrophobic interaction energy between the inhibitors and
their target proteins. Hence in the present investigation we quantitatively evaluate the interac-
tion energies between DPP-4 and its inhibitors by using the first-principles calculations-based
fragment molecular orbital (FMO) quantum-mechanical (QM) method.
The FMO-QM method developed by Kitaura and co-workers [14–16] is a fragmentation
method, through which a system is divided into fragments, for example, each amino acid in
proteins is considered as a fragment, and the total properties of large molecular systems are
derived in a many-body expansion by combining the properties of fragments. In the two-body
method, fragments and their pairs (called as ‘dimers’) are calculated. The calculated interfrag-
ment pair interaction energies, or simply interfragment interaction energies (IFIEs), are used
to analyze the molecular recognition of ligands by proteins. By summing up these IFIEs calcu-
lated for individual fragments, overall binding energy between the ligand and protein can be
estimated, which can be related to the resultant biological potency of the compound as mea-
sured in a biological assay. The correlated FMO calculation provides a complete list of interac-
tions formed between the ligand and protein and so it is suitable for evaluating not only the
electrostatic interactions (important in hydrogen-bonding) but also the van der Waals disper-
sion interactions (hydrophobic interactions) reliably and hence it has been successfully applied
to study a lot of protein-ligand interactions by consistently evaluating their binding energies
[17–21]. Recently, FMO calculations were made to study protein-peptide interactions to
explain the experimental results [22]. In the present work, we use FMO-QM method to quanti-
tatively study the interaction between these DPP-4 inhibitor drugs that are available on the
market and the DPP-4. Particular importance is given to study the interactions at a residue
level and the results are then used to discuss and analyze the inhibitor activities of the drugs
through their structural aspects.
Methods
We performed ab initio FMO calculations to evaluate the interaction energies between various
inhibitor drugs with the DPP-4. These non-covalent type endogenous substrates, sitagliptin 1,
linagliptin 2, alogliptin 3, and teneligliptin 4, are the currently worldwide marketed DPP-4
inhibitor drugs for the treatment of type-2 diabetics. The remaining two covalent type drugs
(saxagliptin 5 and vildagliptin 6) were not considered in this FMO study because binding of
these drugs requires to overcome the energy barrier for the formation of covalent bond between
the nitrile group of their cyanopyrrolidine moieties and the hydroxyl of Ser630 of DPP-4. Evalu-
ating the energy barrier by using the FMO calculation is not a straight forward one.
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The crystal structures of the complexes containing DPP-4 and the inhibitors [sitagliptin 1
(PDB ID: 1X70), linagliptin 2 (2RGU), alogliptin 3 (3G0B), teneligliptin 4 (3VJK)] were taken
from the Protein Data Bank.
At first, we re-refined and rebuilt the atomic coordinates of the crystal structures of these
four DPP-4-inhibitor complexes. The protocols of our re-refinement and re-building the crys-
tal structures of the protein-ligand complex are the following: (i) optimizing the refinement of
the target complex structures using PDB_REDOweb server [23]. This server optimizes various
refinement parameters (including B-factor weight, X-ray weight, TLS groups, bulk solvent
modeling), chooses between an anisotropic or isotropic B-factor model, rebuilds side chains in
rotamer conformations, flips side chains to optimize hydrogen bond networks, checks pep-
tides for ‘flipping’, re-evaluates the water model, and validates all the present ligands, (ii) delet-
ing the sugar chain coordinates, and (iii) making cycles of REFMAC v5.8 [24] maximum-
likelihood positional and B-factor refinements combined with manual remodeling using Coot
[25] until the R and Rfree factors converged. Default procedures were used for the re-refine-
ment using REFMAC program, a part of the CCP4 suite [26], in which generation of restraints
is an entirely automatic process conducted within REFMAC refinement runs when the mono-
mer (ligand) listed in a coordinate PDB file is present in the dictionary with a complete
description. Needless to say, complete description of the amino acids is available in this dictio-
nary. The template-restraint library of CCP4 contains the necessary cifs (crystallographic
information files) of the ligands; however, the cif file for 4 is incomplete and so we used JLi-
gand [27], a CCP4 graphical interface to REFMAC, to generate the necessary cif for this gliptin
to be used by REFMAC for refinement.
Secondly, the missing hydrogen atoms were added by using the Protonate3D module [28]
within Molecular Operating Environment (MOE) program [29]. The orientations of the
added hydrogen atoms were then optimized by using energy minimization scheme through
molecular mechanics calculations utilizing Amber12: EHT force field, which uses Amber12
parameters for macromolecules and extended Huckel theory parameterization for small mole-
cules that takes electronic effects into account, incorporated in MOE program [29]. The final
complex structures were then used for the subsequent FMO calculations. It should be men-
tioned that since all the FMO calculations in the present study were made in vacuum condi-
tion, amino groups of the DPP-4 inhibitors (1–3) were treated as uncharged NH2 groups, to
avoid overestimation of charge-charge electrostatic interactions.
Finally, all-important FMO calculations were made to study the interactions in all the four
selected DPP-4-inhibitor (1, 2, 3, and 4) complexes using the PAICS program [30] at the corre-
lated Resolution-of-Identity second-order Moller Plesset (RI-MP2) level [31–33] with the cc-
pVDZ basis set [34]. In general, in the FMO calculations, each protein-ligand complex struc-
ture is divided into one-residue fragments, with cut-off points at Cα of each residue. Ligand is
also considered as a fragment. For the interaction energy calculation, each amino acid residue
in the protein is allowed to interact with the ligand. In the first step, each monomer (fragment)
is calculated in the Coulomb field exerted by all remaining monomers. This changes the
monomer electron densities and hence the coulomb field they determine. Thus, the monomer
calculations are repeated self consistently. In the second step, each dimer (pair of fragments) is
computed in the Coulomb field exerted by all remaining monomers. By subtracting the two
monomer energies from a dimer energy, one obtains the pair interaction or interfragment
interaction energy (IFIE). Finally, the total energy of the whole system is constructed from the
monomer and the interaction energies. Detailed descriptions of the FMO strategy and meth-
odology can be found in the literature [14–16, 35].
To understand the interacting site, the interfacial buried surface area between DPP-4 and
the inhibitors were calculated using AREAIMOL implemented in the CCP4 program suite with
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a probe radius of 1.4 Å [26]. Fig 2 and Fig 3 were produced using CCP4mg [36] and PyMOL
[37], respectively.
Fig 2. Superposition of the active site of DPP-4-ligand complex structures deposited in Protein databank (ice
blue) and the re-refined and re-built (gold). A σA-weighted FO-FC omit map (3.0σ, in brown mesh) is
superposed on the inhibitors. (a) Sitagliptin 1. (b) Linagliptin 2. (c) Alogliptin 3. (d) Teneligliptin 4.
doi:10.1371/journal.pone.0166275.g002
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Results and Discussion
Improving structures by re-refinement and re-building
Recently, post-deposition optimization is reported to generally improve the protein structures
[38] and therefore to improve the qualities of the selected DPP-4 complex structures for the
FMO calculations, we re-refined and re-built all these complex structures by using PDB_REDO
server, REFMAC v5.8, and Coot. Three out of four re-refined structures have improved Rfree val-
ues (complex structure with linagliptin 0.276! 0.264, alogliptin 0.242! 0.260, teneligliptin
0.279! 0.274, sitagliptin 0.228! 0.213), which is used for cross-validation [39], despite delet-
ing the coordinates of the sugar chains to simplify the subsequent FMO calculations. Especially,
coordinate positions of the inhibitors are improved considerably. The most prominent example
is the structure with the inhibitor 1: the nitrogen atom (N19), of 1, of the deposited structure
(1X70.pdb) has a sp3 hybridized form, but it becomes a sp2 hybridized one after the re-
Fig 3. Binding modes of each inhibitor [(a) sitagliptin 1; (b) linagliptin 2; (c) alogliptin 3; (d) teneligliptin 4] in the active site of DPP-4 complex
structure. S2 ext. (S2 extensive) subsite constructed by Val207, Ser209, Phe357, Arg358, in yellow. S2 subsite constructed by Arg125,
Phe357, Arg358, Glu205, Glu206, Arg669, in light purple. S1 subsite constructed by Ser630, Val656, Trp659, Tyr662, Tyr666, Val711,
Asn710, in orange. S0
1
subsite constructed by Phe357, Tyr547, Pro550, Ser630, Tyr631, Tyr666, in light green. S0
2
subsite constructed by
Tyr547, Trp629, Ser630, His740, in cyan.
doi:10.1371/journal.pone.0166275.g003
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refinement, and the omit map of 1 supports the latter form of the nitrogen (see Fig 2A). A root
mean square deviation (rmsd) of around 0.19 Å is obtained for 1 between its deposited and the
re-refined structures. The coordinate positions of 2 are also improved overall, especially amino-
piperidine motif and butynyl group positions (Fig 2B). The obtained rmsd value for 2, between
its deposited and the re-refined structures, is around 0.21 Å. In the complex structure involving
3, positions of carbon (C9, C10) and nitrogen atoms (N13) of the aminopiperidine motif of 3
are improved (Fig 2C), reflecting in the calculated rmsd value (0.15 Å) for the inhibitor 3
between its deposited and the re-refined structures. The locations of carbon atoms (C15, C18)
and nitrogen atom (N13) of the piperazine moiety in 4 are also moderately improved (Fig 2D).
The calculated rmsd value between the deposited and the re-refined structures for this inhibitor
4 is 0.09 Å. Since some of these atoms or the neighboring ones may involve in the interaction
with the amino acids, it is expected that these structural improvements through re-refining and
re-building procedures would enhance the quality of the results of the subsequent FMO calcula-
tions. The rmsd values, between the deposited and the re-refined structures, for the twenty
amino acids in the protein active site in all these four DPP-4 complex structures were also esti-
mated and the obtained rmsd values were given in S1 Table of the supporting information.
Notable IFIEs between inhibitors and DPP-4
Subsites in the active site of a protease are generally defined by the binding site of the substrate
peptide [40]. The amino acid residues in the substrate peptide are numbered from the point of
cleavage (P2, P1, P
0
1
, P0
2
. . .), and the protein subsites occupied by the respective amino acids
are numbered in the same fashion (S2, S1, S
0
1
, and S
0
2
. . .). In the present case, the N-terminus
of the substrate peptide is recognized by Glu205, Glu206, and Ser630 cleaves at the N-terminus
penultimate position (P1). We used the same definition for these four subsites in the present
study. In addition to these four subsites, S2 extensive subsite, the site beyond S2 that is sup-
posed to involve in the interaction, is defined as that by Nabeno et al. [10]. This site is com-
posed of Val207, Ser209, Phe357, and Arg358.
The inhibitor binding leads to two important changes in the DPP-4 structure: (1) Tyr547
makes a conformational change, with the binding of 2 and 3, so to have a π-π stacking interac-
tion with the uracil moieties of 2 and 3. No such conformational change in Tyr547 is noticed,
however, with the binding to the other two inhibitors and (2) Arg358 goes for a side-chain
reorientation with the binding of 1 and 4 that enables the opening of the S2 extensive subsite,
in which trifluoromethyl and phenyl moieties of 1 and 4, respectively, occupy. This paves the
way for these two inhibitors to interact to S2 extensive subsite.
Fig 3 represents the binding mode of various inhibitors in the active site of the DPP-4. As
shown in the Figs 2 and 3 interact to S1, S2, S
0
1
, and S
0
2
subsites (Fig 3B and 3C), and 1 and 4
bind to S1, S2, S
0
1
, and S2 extensive subsites (Fig 3A and 3D). Overall, these DPP-4 inhibitors
reside inside the hydrophobic cavity made up of Arg125, Glu205, Glu206, Tyr547, Tyr662,
Tyr666, Ser630, and Phe357.
Interfragment interaction energies calculated between the four selected inhibitors and sev-
eral subsite residues of the DPP-4 are depicted in Fig 4A–4D. As it is mentioned in the Intro-
duction section, both electrostatic and dispersion interactions can be studied and quantified
separately using FMO calculations. It is known that DPP-4 inhibitors interact strongly with
the Glu206 and Glu205 amino acids in the S2 subsite by forming salt bridges with them. The
calculated IFIEs of these residues with all the inhibitors are large and especially Glu206 has the
largest IFIE with all the considered inhibitors. One of the notable differences is that IFIE calcu-
lated between Glu205 and the inhibitor 4 is much smaller than those obtained between the
same Glu and the other inhibitors. A close look at the complex structures reveals that
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inhibitors interact with these Glu205 and Glu206 amino acids by not only forming salt bridges
but also effectively making hydrogen bonding with them and so this interaction should be con-
sidered as a combination of charge-charge and hydrogen bonding electrostatic interactions. In
the case of Glu206 interacting with the inhibitors, both the oxygen atoms of its carboxyl group
make strong hydrogen bonds (with 1.9 Å and 2.3 Å bond lengths) with the hydrogen atoms of
the inhibitors; however, it is only one of the oxygen atoms, of the carboxyl group, of Glu205
forms a hydrogen bonding (1.8 Å) with the inhibitors. The other oxygen atom of this glutamic
acid makes a strong hydrogen bonding (with 1.8 Å bond length) interaction with Arg125. This
is one of the reasons for why inhibitors have larger IFIEs (mostly due to the electrostatic inter-
action) with Glu206 than those with Glu205. In the case of 4, its interaction with Glu206 is
similar to those of the other inhibitors, but its hydrogen bonding interaction with Glu205 is
weaker (bond length of 2.5 Å), when compared with those of other inhibitors, and hence
decrease in the calculated IFIE.
Let us see the nature of the other important interactions of DPP-4 with of its each inhibitors
separately. In the case of 2, its 2-butynyl group that resides in the S1 pocket interacts with
Tyr662, Ser630, and Tyr666. As mentioned by Nabeno et al. [10], 2 interacts with Try547
Fig 4. Interfragment interaction energy (IFIE) between amino acid residues at the active site of DPP-4 and the inhibitors [(a) sitagliptin 1, (b)
linagliptin 2, (c) alogliptin 3, (d) teneligliptin 4]. The electrostatic (gray) and van der Waals (black) interaction energies are shown separately.
doi:10.1371/journal.pone.0166275.g004
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through its uracil moiety by forming a π-π stacking (distance between the rings is 3.1 Å); how-
ever, in addition to this π-π interaction, its imidazole group also interacts with the same tyrosine
residue through OH-π interaction (distance is 2.9 Å). This strong interaction reflects in the cal-
culated IFIE value, -15.28 kcal/mol (van der Waals dispersion interaction amounts -19.08 kcal/
mol and the repulsive electrostatic interaction is 3.80 kcal/mol, Fig 4B). Methylquinazolinone
interacts strongly with Try629 (-11 kcal/mol) by not only making π-π interaction with both phe-
nyl and pyrrole ring of the tryptophan through its phenyl component of the quinazoline moiety
but also by interacting via CH-π interaction (2.7 Å) through its pyrimidine ring. In addition to
the interaction with 2-butynyl group, Tyr666 also makes a CH-π interaction with the piperidine
ring (2.7 Å). The overall IFIE calculated with this tyrosine is -3.90 kcal/mol (van der Waals dis-
persion interaction is -6.50 kcal/mol and the repulsive electrostatic interaction is 2.60 kcal/mol).
The piperidine ring also interacts with Phe357 ring through CH-π interaction (3.0 Å with
around -3 kcal/mol strength).
Interaction of 4 with the DPP-4 is interesting. Apart from the strong interaction with
Glu206, it has one other significant hydrogen bonding. Its carbonyl group forms a strong
hydrogen bonding with Asn710 (2.1 Å). Its thiazoline moiety interacts with Tyr662, and its
pyrrolidine ring also interacts with the same tyrosine via hydrogen bonding. This combined
interaction results in a larger IFIE (-10.60 kcal/mol, Fig 4D) than that seen in the case of 2 (Fig
4B). The other two main interactions come through Tyr666 and Phe357. The CH groups of
thiazoline form CH-π interactions with Tyr666 ring and the overall calculated IFIE is -7.62
kcal/mol (van der Waals dispersion interaction -12.89 kcal/mol, electrostatic interaction 5.27
kcal/mol). The piperazine moiety of 4 interacts with Phe357 through CH-π mode and the IFIE
is calculated to be -8.94 kcal/mol (with -11.61 kcal/mol contribution from van der Waals dis-
persion interaction and 2.68 kcal/mol through electrostatic interaction). The present study
also showed that this inhibitor has moderate interactions with Arg358 (IFIE of -6.78 kcal/mol)
and Ser209 (IFIE of -3.75 kcal/mol).
In the case of 3, its cyanobenzyl moiety that resides in the subsite S1 interacts with Tyr662,
Tyr666, and Ser630, and the calculated overall IFIEs are -7.10, -8.25, and -5.38 kcal/mol,
respectively (Fig 4C). The uracil moiety makes a moderate π-π interaction with Tyr547 (3.4
Å), which accounts -9.70 kcal/mol energy and the overall IFIE with this tyrosine is calculated
to be -7.00 kcal/mol. Inhibitor 3 interacts also with Tyr631 through its cyanobenzyl group
(CH-π) as well through carbonyl group of its uracil moiety (hydrogen bonding).
Sitagliptin 1 forms the strongest bonding with Glu206 and Glu205 (Fig 4A) residues
through its amine group (OH bond lengths are as small as 1.7 and 1.8 Å). The present calcu-
lation reveals that its trifluorophenyl ring that binds to the S1 subsite has only moderate inter-
actions with Tyr662 and Tyr666. The other strong interaction comes through Phe357 –the
triazolopyrazine moiety π-π stacks with this phenylalanine and the calculated IFIE is -10.64
kcal/mol. CF3 group interacts moderately with Arg358.
Comparison of IFIEs: linagliptin vs alogliptin and teneligliptin vs
sitagliptin
On the basis of their binding subsites [10], 2 and 3 belong to Class II category (binds to S1, S2,
S
0
1
, and S
0
2
subsites) and 1 and 4 belong to Class III category (binds to S1, S2, S
0
1
, and S2 extensive
subsites).
Among the two xanthine-based inhibitor drugs, 2 showed 8-fold higher activity than 3, and
Nabeno et al. [10] noted that one of the reasons for this superior activity might be due to the
fact that only 2 can engage interacting at the S
0
2
subsite. The present study supports this fact
that phenyl component of the quinazolinone moiety (of 2) makes a formidable interaction
Comparative Binding Analysis of DPP-4 with Antidiabetic Drugs—A Fragment Molecular Orbital Study
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with Trp629 by forming π-π stacking with phenyl as well as with pyrrole ring of this trypto-
phan residue. In addition to this, the pyrimidine ring of this quinazolinone forms a CH-π
interaction with this tryptophan and these combined interactions resulted into a strong bind-
ing of over -11 kcal/mol. This is completely absent in 3. One other important factor that sepa-
rates these two inhibitors is their interactions with Tyr547. While 3 interacts (π-π stacking)
with Tyr547 through its uracil substructure, 2 interacts with the same tyrosine through both of
its uracil (π-π) and imidazole (OH-π) moieties. This has been evidenced from the calculated
hydrophobic IFIE values: -19.1 and -9.7 kcal/mol for 2 and 3, respectively. All these factors
might have caused the superior activity of 2. It should be mentioned that the binding affinity
of 2 towards DPP-4 is predicted to be higher than that of 3 [10, 41] and its IC50 value is smaller
[12, 42]. Recent binding kinetics studies on these ligands using SPR have also supported this
prediction [12]. Large binding affinity predicted for the inhibitor 2 might be attributed mainly
to the unique existence of its strong interactions with Trp629 and Tyr547 residues at S
0
2
subsite.
The presence of the triazolopiperazine and piperazine moiety in 1 and 4, respectively, at the
P2 position makes 4 and 1 to engage in interaction at the S2 extensive subsite and introduces
the “anchor lock domain” resulting in an increase of the binding activity owning to stronger
hydrophobic interactions [10] at this subsite. As it has been mentioned earlier, 4 has the weak-
est interaction with Glu205, but it has 5-fold higher activity than 1. So, this superior activity of
4 should have come from other quarters. It has been concluded in previous studies [10, 43]
that interaction at S2 extensive subsite by 1 and 4 contributes to increase in their inhibitory
activities. Among these two inhibitors, 4 has a larger contact area (0.92 nm2) in the S2 extensive
subsite than 1 has (0.71 nm2) and, it has been concluded by Nabeno et al. [10] that the former
may bind more tightly to this extensive subsite and this might be one of the reasons for its
larger inhibitory activity. Though the present study supports this fact that the interaction of 4
with Phe357, Arg358, Ser209, and Val207 at this S2 extensive subsite is marginally stronger
(Fig 4A & 4D), the difference in interaction energies is not a significant one to explain the
higher inhibitory activity of 4. Careful analysis reveals that it is not just the S2 extensive subsite
but also S1 subsite that provides the room for 4 to have a stronger interaction with DPP-4: (1)
its carbonyl group forms a strong hydrogen bond with Asn710 and (2) its interaction with
Typ666 ring is doubly stronger (calculated hydrophobic interaction energy between 4 and 1
with Tyr666 is -12.89 and -6.40 kcal/mol, respectively).
Comparing 2 and 4 provides some interesting outcome: the main difference in their inter-
action pattern is that the former interacts strongly at S
0
2
subsite and the latter has some signifi-
cant interactions at S2 extensive subsite. The IC50 value obtained for 2 is smaller than that
obtained for 4 [12, 42]. This affords an assertion that strong hydrophobic interactions at S
0
2
subsite is more crucial, than the interactions at S2 extensive subsite, for an efficient DPP-4
inhibitor drug.
Correlation between inhibitor activity and its hydrophobic IFIE with
DPP-4
It should be mentioned that the calculated FMO-IFIE is not the difference between the energy
of the protein–ligand complex and the sum of the energies of the ‘free’ protein and ligand but
rather represents the “strength” of the interactions between the ligand and protein residues in
the complex. The total IFIEs (sum of all the IFIEs) describe the stability of the protein-ligand
complex. This stability correlates with, but is not the same as, the binding energy. By keeping
this fact in mind, we compared the calculated IFIEs with the experimental binding energies
and potencies to check whether there is any correlation between them.
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Table 1 shows that number of non-hydrogen atoms of the inhibitors correlates well with
the interfacial buried surface area (R2 = 0.95). These two factors correlate moderately with the
calculated hydrophobic IFIEs (between DPP-4 and the inhibitors) with R2 value of 0.579 and
0.662, respectively. These observations are consistent with the trend predicted for the PPI
inhibitors that the number of non-hydrogen atoms of these inhibitors correlates nicely with
their binding energies with the proteins [44] in which the interactions are mainly composed
by hydrophobic ones [45]. Notably, the calculated hydrophobic IFIEs of the inhibitors (with
DPP-4) correlate well with their pIC50 values [10, 42] with R2 of 0.85 (Fig 5A). This outcome is
coherent with the trend obtained for the PPI that their binding affinities correlate with their
Van der Waals energies [46]. We also compared the calculated hydrophobic IFIEs with the
recently [12] observed binding affinities, KD from SPR data, of various inhibitor drugs to the
DPP-4 (Fig 5B indicates the calculated IFIEs vs experimental pKD values) and found a moder-
ate correlation (R2 = 0.69). By considering the fact that the binding affinity is not only depend-
ing on specific interactions obtained by FMO but also depends on other factors such as
entropy, desolvation, and strain energy present in the ligand’s bioactive conformation, this
correlation could be considered as a significant one. These calculated hydrophobic IFIEs also
have good correspondence with the SPR-derived off-rates and residence times [12]. All these
observations reveal that hydrophobic interactions play an essential role in the inhibitory activi-
ties of these DPP-4 inhibitors. Subsequently, larger endogenous substrates, which could cover
the sizeable DPP-4 active site of the hydrophobic pocket extensively, could provide increased
inhibitory activities than by smaller inhibitors even with higher binding energies.
Fig 5. Relationship between hydrophobic IFIE (kcal/mol), calculated between the inhibitors and DPP-4, and (a)
inhibitor activity [pIC50] (values taken from Ref. 10 and 42) and (b) experimental binding affinity [pKD] of the
inhibitors from surface plasmon resonance (SPR) data (values taken Ref. 12).
doi:10.1371/journal.pone.0166275.g005
Table 1. Correlation between number of non-hydrogen atoms of ligands and the interfacial buried
surface area with chain A of DPP-4. The correlation coefficient is 0.97.
Number of non-hydrogen atoms Interfacial buried surface area (Å2)
Sitagliptin 1 28 265.9
Linagliptin 2 35 318.3
Alogliptin 3 25 233.6
Teneligliptin 4 30 293.9
doi:10.1371/journal.pone.0166275.t001
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Conclusions
Through the present investigation, interaction between the DPP-4 and its inhibitor drugs were
quantitatively studied by using quantum mechanical fragment molecular orbitals method at
correlated RI-MP2/cc-pVDZ level. The present residue-level interaction study reveals that
though all the inhibitors generally form strong interactions with Glu205 and Glu206 amino
acids through forming salt bridges as well as by effectively making hydrogen bonds with them,
the effectual interactions exist at S
0
2
subsite, for the linagliptin 2 and alogliptin 3, and S2 exten-
sive and S1 subsites, for sitagliptin 1 and teneligliptin 4. The superior inhibitory activities of 2
and 4 were thoroughly investigated by elaborately studying the interaction between the DPP-4
and its inhibitors. Hydrophobic IFIEs correlate well with the activities of the DPP-4 inhibitors.
The study concludes that interactions, especially the hydrophobic ones, at the S
0
2
, S2 extensive,
and S1 subsites are crucial. Among others, interactions with Try547 and Trp629, for the cate-
gory II inhibitors, and with Phe357 and Tyr666, for the category III inhibitors, are decisive for
their DPP-4 inhibitory activities.
Hence, inhibitors covering the DPP-4 active site significantly interact extensively with the
hydrophobic pocket by their hydrophobic inhibitor moieties. The cumulative strength of these
hydrophobic interactions becomes large for these inhibitors and therefore linagliptin and tene-
ligliptin have larger interaction energies, and consequently higher inhibitory activities, than
their alogliptin and sitagliptin counterparts. The present conclusions can be used effectively to
search novel new inhibitors of DPP-4.
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